Withdrawal of anticancer therapy in advanced disease: a systematic literature review
2015
Background
Current guidelines set out when to start anticancer treatments, but not when to stop as the end of life approaches. Conventional cytotoxic agents are administered intravenously and have major life-threatening toxicities. Newer drugs include molecular targeted agents (MTAs), in particular, small molecule kinase-inhibitors (KIs), which are administered orally. These have fewer life-threatening toxicities, and are increasingly used to palliate advanced cancer, generally offering additional months of survival benefit. MTAs are substantially more expensive, between £2-8 K per month, and perceived as easier to start than stop.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
85
References
35
Citations
NaN
KQI